Abstract Background A previous European Headache Federation (EHF) guideline
addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide …

Background Direct comparisons of the tolerability and safety of migraine preventive
treatments targeting the calcitonin gene-related peptide pathway are lacking. This study …

Background The clinical benefit of galcanezumab, demonstrated in randomized clinical trials
(RCTs), remains to be quantified in real life. This study aimed at evaluating the effectiveness …

Background The monoclonal antibody eptinezumab, which targets calcitonin gene-related
peptide, has shown migraine preventive effects starting the day following infusion and …

Background Switching between antibody classes might be a treatment option in migraine
patients who have not responded to one class of a CGRP-(receptor) monoclonal antibody …

Background Several drugs are available for the preventive treatment of both episodic and
chronic migraine. The choice of which therapy to initiate first, second, or third is not …

Background Fremanezumab has demonstrated to be effective, safe, and tolerated in the
prevention of episodic or chronic migraine (CM) in randomized, placebo-controlled trials …

Migraine is an extremely disabling, common neurological disorder characterized by a
complex neurobiology, involving a series of central and peripheral nervous system areas …

Objective While there are several trials that support the efficacy of various drugs for migraine
prophylaxis against placebo, there is limited evidence addressing the comparative safety …

Background National and international guidelines recommend stopping migraine
prophylaxis with CGRP (-receptor) monoclonal antibodies after 6–12 months of successful …